Biomarkers in lupus nephritis.
Biomarkers have the potential to be useful tools for noninvasively evaluating and managing patients with lupus nephritis. Many candidate biomarkers have been identified, but they require validation in larger cohorts. It is likely that combinations or biomarker profiles, rather than individual markers, will emerge to help better predict the severity of inflammation, the extent of fibrosis, degree of drug responsiveness, and other variables. This approach has the potential to reduce the use of the renal biopsy, improve therapeutic efficacy, and limit toxicity. We predict algorithms based on genotype and biomarkers combined with clinical presentation will emerge to help guide physicians in management. Assays that show the most potential include serum erythrocyte bound complement C4d, interleukin 17, interleukin 23, interferon score/chemokine score ratio, and anti-C1q antibodies. Such urinary biomarkers as fractional excretion of endothelial-1, monocyte chemoattractant protein-1, vascular cell adhesion molecule-1, and TWEAK (tumor necrosis factor-like weak inducer of apoptosis) may also be useful but require validations.
Manoharan
Anup
A
Department of Medicine, Nephrology and Kidney Transplantation Section, Medical College of Georgia, 1120 15th Street, BA 9413, Augusta, GA 30912-3140, USA. AMANOHARAN@mail.mcg.edu
Madaio
Michael P
MP
D001323:Autoantibodies / Q000097:blood; D015415:Biomarkers / Q000097:blood / Q000652:urine; D018925:Chemokines / Q000097:blood* / Q000652:urine*; D006801:Humans; D008181:Lupus Nephritis / Q000097:blood* / Q000652:urine*; D012698:Serologic Tests
D001323:Autoantibodies; D015415:Biomarkers; D018925:Chemokines